Creabilis appoints David Roblin CMO
This article was originally published in Scrip
Executive Summary
Creabilis, a clinical stage biotech, has appointed Dr David Roblin chief medical officer. Dr Roblin was most recently Pfizer's senior vice-president, head of research and site head for European R&D. He previously chaired the Research Director's Group of EFPIA, and is currently an advisor at NOCRI in the NHS and a non-executive director of Xceleron.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.